Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTGQUFK)

• DTT Name: PI3K/AKT/mTOR pathway (PAm pathway)
• Gene Name: NO-GeName
• DTT Type: Successful target; [1]
• Related Disease:
  Multiple myeloma [ICD-11: 2A83]
  Transplant rejection [ICD-11: NE84]
• UniProt ID: NOUNIPROTAC
• TTD ID: T90695

Molecular Interaction Atlas (MIA) of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sirolimus	DMGW1ID	Multiple myeloma	2A83	Approved	[1], [2], [3]

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ON-01210.Na	DMWYEDX	Acute radiation syndrome	NF00	Phase 1	[4]

1 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glypromate	DM07VBW	Neurological disorder	6B60	Discontinued in Phase 2	[5]

References

• [1] The genomic landscape of nasopharyngeal carcinoma.Nat Genet. 2014 Aug;46(8):866-71.
• [2] An orthotopic model of metastatic nasopharyngeal carcinoma and its application in elucidating a therapeutic target that inhibits metastasis.Genes Cancer. 2011 Nov;2(11):1023-33.
• [3] Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma.Cancer Res. 2004 Aug 1;64(15):5251-60.
• [4] ON01210.Na (Ex-RAD ) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013;8(3):e58355.
• [5] Dendritic spine dysgenesis in Rett syndrome. Front Neuroanat. 2014; 8: 97.